Question: Can you tell me about the effect of the MTHFR gene on antidepressant medications?

Answer: I'm sorry, but the information provided in the prompt does not include details about the effect of the MTHFR gene on antidepressant medications. It's important to consult with a healthcare provider or a genetic counselor for personalized advice based on your specific genetic makeup.
Sources:
page_content='Clin Pharmacol Ther 2007;81:699-707.6. Johnson M et al. A poor metabolizer for cytochromes P450 2D6 and 2C19: a case report on antidepressant treatment. CNS Spectr 2006;11:757-60.7. Stephan PL et al. Adverse drug reactions following nonresponse in a depressed patient with CYP2D6 deficiency and low CYP 3A4/5 activity. Pharmacopsychiatry 2006;39:150-2.8. Kirchheiner J et al. Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. J Clin Psychopharmacol 2004;24:647-52.9. Grasmader K et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J ClinPharmacol 2004;60:329-36.10. Murphy GM Jr et al. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003;160:1830-5.Date 18-05-2020CYP2D6 UM: mirtazapine2003NO action is required for this gene-drug interaction.The effect on the' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='efficacy in depressed patients treated in psychiatric settings?Pharmacogenomics 2017;18:639-50.2. Jiang F et al. The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes. Psychopharmacology (Berl)2015;232:1899-909.3. Brandl EJ et al. Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder. Pharmacogenomics J 2014;14:176-81.4. Shams ME et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 2006;31:493-502.5. Veefkind AH et al. Venlafaxine serum levels and CYP2D6 genotype. Ther Drug Monit 2000;22:202-8.Date 04-03-2019CYP2C19 IM: voriconazol1683The gene variation can reduce the conversion of voriconazole and consequently increase the plasma concentration. This could result in improved efficacy or an increase in the risk of side effects.Recommendation:Monitor the plasma concentrationLiterature:1. Li X' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='for this gene-drug interaction.The effect on the plasma concentration of mirtazapine is small. No effect has been demonstrated with regard to effectiveness or side effects.Literature:1. Jaquenoud Sirot E et al. Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression. J Clin Psychopharmacol 2012;32:622-9.2. Lind AB et al. Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour. ClinPharmacokinet 2009;48:63-70.3. Brockmoller J et al. Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects. Clin Pharmacol Ther 2007;81:699-707.4. Kirchheiner J et al. Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. J Clin Psychopharmacol 2004;24:647-52.5.' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='obsessive-compulsive disorder. Pharmacogenomics J 2014;14:176-81.4. Hamelin BA et al. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther 1996;60:512-21.Date 14-05-2018CYP2D6 UM: sertraline3514This is NOT a gene-drug interaction.Literature:1. Saiz-Rodr√≠guez M et al. Effect of polymorphisms on the pharmacokinetics, pharmacodynamics and safety of sertraline in healthy volunteers. Basic Clin Pharmacol Toxicol 2018;122:501-511.2. Brandl EJ et al. Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder. Pharmacogenomics J 2014;14:176-81.Date 14-05-2018SLCO1B1 521CC: simvastatine4056When using simvastatin 80 mg/day, the risk of myopathy is increased 30-fold to 18% and the risk of severe myopathy is increased 48-fold to 12%. When using 40 mg/day, this risk is increased 7-fold to 1% and 11-fold to0.68% respectively. The gene variation leads to reduced simvastatin transport to the' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='effects of antidepressants in a naturalistic clinical setting. Eur J ClinPharmacol 2004;60:329-36.6. Wang JH et al. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin Pharmacol Ther 2001;70:42-7.' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='in a large group of depressed patients. Pharmacogenomics J 2010;10:219-25.2. Schenk PW et al. Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients. Mol Psychiatry 2008;13:597-605.3. Morinobu S et al. Effects of genetic defects in the CYP2C19 gene on the N-demethylation of imipramine, and clinical outcome of imipramine therapy. Psychiatry Clin Neurosci 997;51:253-7.4. Madsen H et al. Imipramine demethylation in vivo: impact of CYP1A2, CYP2C19, and CYP3A4. Clin Pharmacol Ther 1997;61:319-24.5. Koyama E et al. Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4-hydroxylation status in Japanese depressive patients. J Clin Psychopharmacol 1996;16:286-93.6. Madsen H et al. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study. Br J Clin Pharmacol 1995;39:433-9.7. Koyama E et al. Metabolic disposition of' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='J Clin Psychopharmacol 2004;24:647-52.5. Grasmader K et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J ClinPharmacol 2004;60:329-36.Date 18-05-2020CYP2C19 IM: moclobemide1991NO action is needed for this gene-drug interaction.Although the moclobemide plasma concentration may increase as a result of the decreased CYP2C19 activity, this does not lead to an increased incidence of side effects, in as far as is known.Literature:1. Gram LF et al. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther 1995;57:670-7.2. SPC Aurorix.Date 04-03-2019CYP2C19 PM: moclobemide1992NO action is needed for this gene-drug interaction.Although the moclobemide plasma concentration may increase as a result of the decreased CYP2C19 activity, this does not lead to an increased incidence of side effects, in as far' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='pharmacokinetic analysis of mirtazapine. Eur J Clin Pharmacol 2004;60:473-80.8. Murphy GM Jr et al. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003;160:1830-5.Date 18-05-2020CYP2D6 PM: mirtazapine2001NO action is required for this gene-drug interaction.The higher plasma concentration of mirtazapine does not result - or hardly results - in an increase in the side effects.' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='J et al. Possible impact of the CYP2D6*10 polymorphism on the nonlinear pharmacokinetic parameter estimates of paroxetine in Japanese patients with major depressive disorders. Pharmgenomics PersMed 2014;7:121-7.3. Murata Y et al. Severe sleepiness and excess sleep duration induced by paroxetine treatment is a beneficial pharmacological effect, not an adverse reaction. J Affect Disord 2013;150:1209-12.4. Murata Y et al. Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome. J Clin Psychopharmacol 2010;30:11-7.5. Ververs FF et al. Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy. Clin Pharmacokinet 2009;48:677-83.6. Van Nieuwerburgh FC et al. Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms. Int J Psychiatry Clin Pract 2009;13:345-348.7. Gex-Fabry M et al. CYP2D6 and ABCB1 genetic variability:' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='20531370.3. Mrazek DA et al. CYP2C19 variation and citalopram response. Pharmacogenet Genomics 2011;21:1-9. PubMed PMID: 21192344.4. Peters EJ et al. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS One 2008;3:e1872. PubMed PMID: 18382661.5. Grasmader K et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J ClinPharmacol 2004;60:329-36.6. Herrlin K et al. Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. Br J Clin Pharmacol 2003;56:415-21.7. Bondolfi G et al. Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation. Psychopharmacology 1996;128:421-5.8. Sindrup SH et al. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='is not known whether it is possible to reduce the dose to such an extent that the side effects disappear, while the effectiveness is maintained. In general, it is assumed that the effectiveness is determined bythe sum of the plasma concentrations of venlafaxine and O-desmethylvenlafaxine. However, the side effects do not appear to be related to this sum.Furthermore, a reduced effectiveness of venlafaxine has been observed in depression patients with this gene variation.Literature:1. Taranu A et al. Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings?Pharmacogenomics 2017;18:639-50.2. Berm E et al. Relation between CYP2D6 genotype, phenotype and therapeutic drug concentrations among nortriptyline and venlafaxine users in old age psychiatry. Pharmacopsychiatry 2016;49:186-190 enpersoonlijke communicatie (correctie: totaal aantal pati√´nten met sub- and' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='patients with neuropathic pain shows significant association to serotoninreceptor2C (HTR2C). Eur J Clin Pharmacol 2011; 67:1131-7.13. Tsai et al. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics 2010:11;537-46.14. Noehr-Jensen et al. Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker. Eur J Clin Pharmacol 2009;65:887-94.15. Jin Y et al. Effect of age, weight, and CYP2C19 genotype on escitalopram exposure. J Clin Pharmacol. 2010;50:62-72.16. Rudberg I et al. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther 2008;83:322-7.17. SPC‚Äôs Lexapro (NL en VS).Date 14-05-2018CYP2C19 UM: escitalopram1820The risk of conversion to another antidepressant is increased as the gene variation leads to a reduction in the escitalopram plasma concentration.avoid' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}


Question: What pharmacogenomic factors in the IFNL3 gene are important when prescribing antivirals?

Answer: I'm sorry, but the information provided in the prompt does not include specific details about the pharmacogenomic factors in the IFNL3 gene that are important when prescribing antivirals. Therefore, I cannot provide a detailed response to your question. Please consult a healthcare professional or a relevant source for this information.
Sources:
page_content='\x0626. Clin Infect Dis 2007;45:1230-7. PubMed PMID: 17918089.17. Burger D et al. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol2006;61:148-54.18. Haas DW et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult Aids Clinical Trials Group study. J Infect Dis 2005;192:1931-42. PubMed PMID:16267764.' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='Mart√≠n AS et al. Dose reduction of efavirenz: an observational study describing cost-effectiveness, pharmacokinetics and pharmacogenetics. Pharmacogenomics 2014;15:997-1006.9. Bertrand J et al. Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia. J InfectDis 2014;209:399-408.10. Sarfo FS et al. Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients. J Antimicrob Chemother 2014;69:491-9.PubMed PMID: 24080498.11. Ngaimisi E et al. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.PLoS One 2013;8:e67946. PubMed PMID: 23861838.12. Yimer G et al. High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='fatigue induced by irinotecan-based chemotherapy. Cancer2006;106:1007-16.24. Wright MA et al. A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors.Clin Cancer Res 2005;11:4144-50.25. Kweekel DM et al. Ondersteuning van de chemotherapiekeuze. Pharm Weekblad 2005;20:685-7.26. Steiner M et al. 5-fluorouracil/irinotecan induced lethal toxicity as a result of a combined pharmacogenetic syndrome: report of a case. J Clin Pathol 2005;58:553-5.27. Soepenberg O et al. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors. Clin Cancer Res 2005;11:1504-11.28. Zhou Q et al. Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. Br J Clin Pharmacol 2005;59:415-24.29. Marcuello E et al. UGT1A1 gene variations and irinotecan treatment in' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='\x0628. Pharmacogenet Genomics 2007;17:497-504.15. Stewart CF et al. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. J Clin Oncol 2007;25:2594-600.16. C√¥t√© JF et al. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 2007;13:3269-75.17. Ramchandani RP et al. The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. J Clin Pharmacol 2007;47:78-86.18. Z√°rate Romero R et al. Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients. Oncol Rep' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='with cytochrome P450 2B6 *6 and *26. Clin Infect Dis 2007;45:1230-7. PubMed PMID: 17918089.19. Haas DW et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult Aids Clinical Trials Group study. J Infect Dis 2005;192:1931-42. PubMed PMID:16267764.20. SPC‚Äôs Efavirenz Mylan en Sustiva (VS).21. ENCORE1 Study Group. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial.Lancet 2014;383:1474-82.Date 05-03-2018CYP2D6 IM: eliglustat6138This gene variation reduces the conversion of eliglustat to inactive metabolites. However, in the absence of CYP2D6 and CYP3A inhibitors, this does not result in a clinically significant increased risk of side effects.Recommendation:Co-medication with BOTH a MODERATE to STRONG CYP2D6 INHIBITOR AND a MODERATE to STRONG CYP3A INHIBITOR:Eliglustat is contra-indicated.1.' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='3. Goetz MP et al. UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine. Invest New Drugs 2013;31:1559-67.4. Denlinger CS et al. Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol 2009;65:97-105.5. Minami H et al. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1\x07\x06\x08' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content="for optimal efavirenz exposure in children 3-36 months with HIV infection. AIDS 2017;31:1129-1136.3. Leger P et al. Pharmacogenetics of efavirenz discontinuation for reported central nervous system symptoms appears to differ by race. Pharmacogenet Genomics 2016;26:473-80.4. Cusato J et al. Efavirenz pharmacogenetics in a cohort of Italian patients. Int J Antimicrob Agents 2016;47:117-23.5. Dickinson L et al. Comprehensive pharmacokinetic, pharmacodynamic and pharmacogenetic evaluation of once-daily efavirenz 400 and 600 mg in treatment-na√Øve HIV-infected patients at 96 weeks: results of theENCORE1 study. Clin Pharmacokinet 2016;55:861-73.6. Swart M et al. An expanded analysis of pharmacogenetics determinants of efavirenz response that includes 3'-UTR single nucleotide polymorphisms among black South African HIV/AIDS patients. Front Genet2016;6:356.7. Meng X et al. Effect of CYP2B6 gene polymorphisms on efavirenz plasma concentrations in Chinese patients with HIV infection. PLoS One" metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='J Natl Cancer Inst 2007;99:1290-5.18. Minami H et al. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1\x07\x06\x08' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.PLoS One 2013;8:e67946. PubMed PMID: 23861838.13. Yimer G et al. High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of na√Øve HIV patients from Ethiopia: a prospective cohort study.Pharmacogenomics J 2012;12:499-506. PubMed PMID: 21862974.' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='IM: irinotecan1691NO action is needed for this gene-drug interaction.This genetic variation (IM) is more common in Western populations than the wild-type (&\x01\x03*1). This means that treatment is largely geared to patients with this genetic variation. Adjustment of the treatment is thereforenot useful.Literature:1. Chen X et al. UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with lung cancer: a meta-analysis. Cancer Chemother Pharmacol 2017;79:1109-1117.2. Chen YJ et al. The association of UGT1A1\x07\x06\x08' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='Thrombolysis 2015; 39:228-34.2. Xu H et al. Meta-analysis of efficacy and safety of genotype-guided pharmacogenetic dosing of warfarin. Int J Cardiol 2014; 177:654-7.3. Franchini M et al. Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis. J Thromb Haemost 2014; 12:1480-7.4. Stergiopoulos K et al. Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials. JAMA Intern Med 2014; 174:1330-8.5. Yang J et al. Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis. Int J Cardiol 2013; 168:4234-43.6. Jorgensen AL et al. Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS One 2012; 7:e44064.7. Lindh JD et al. Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='with efavirenz-based HAART-induced liver injury in the treatment of na√Øve HIV patients from Ethiopia: a prospective cohort study.Pharmacogenomics J 2012;12:499-506. PubMed PMID: 21862974.13. Mugusi S et al. Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania. PLoS One 2012;7:e40180. PubMed PMID:22808112.14. Wyen C et al. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. J Antimicrob Chemother2011;66:2092-8. PubMed PMID: 21715435.15. Carr DF et al. Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort. J Antimicrob Chemother 2010;65:1889-93. PubMed PMID: 20639527.16. Gatanaga H et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 \x07\x06\x08' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}


Question: How do BRCA1 mutations influence chemotherapy selection in cancer patients?

Answer: I'm sorry, but the information provided in the prompt does not include details about how BRCA1 mutations influence chemotherapy selection in cancer patients. Therefore, I cannot provide an accurate response to your question. Please consult with a healthcare professional for this information.
Sources:
page_content='Patients with the SLCO1B1 Diplotype *38/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *1/*46 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *36/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *28/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *31/*36 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *26/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *33/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *39/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *15/*36 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *5/*38 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *23/*26 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *9/*36 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}


Question: How do APOE gene variants affect the response to anticoagulants?

Answer: I'm sorry, but the information provided in the prompt does not include details on how APOE gene variants affect the response to anticoagulants. It's important to consult with a healthcare provider or a genetic counselor for personalized advice based on a comprehensive understanding of your genetic profile and overall health.
Sources:
page_content='2010;66:253-60.7. Wijnen PA et al. Variant VKORC1 and CYP2C9 alleles in patients with diffuse alveolar hemorrhage caused by oral anticoagulants. Mol Diagn Ther 2010;14:23-30.8. Stepien E et al. A vitamin K epoxide reductase-oxidase complex gene polymorphism (-1639G>A) and interindividual variability in the dose-effect of vitamin K antagonists. J Appl Genet 2009;50:399-403.9. Teichert M et al. Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period. Clin Pharmacol Ther2009;85:379-86.10. Montes R et al. The influence of polymorphisms of VKORC1 and CYP2C9 on major gastrointestinal bleeding risk in anticoagulated patients. Br J Haematol 2008;143:727-33.11. Markatos CN et al. VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients. Pharmacogenomics 2008;9:1631-8.12. Spreafico M et al. Effects of CYP2C9 and VKORC1 on INR variations and dose requirements' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='phase of anticoagulant therapy. Pharmacogenomics 2008;9:1237-50.18. Gonz√°lez-Conejero R et al. The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol. J Thromb Haemost 2007;5:1701-6.19. Beinema MJ et al. The influence of NSAIDs on coumarin sensitivity in patients with CYP2C9 polymorphism after total hip replacement surgery. Mol Diagn Ther 2007;11:123-8.20. Mark L et al. Cytochrome P450 2C9 polymorphism and acenocoumarol therapy. Kardiol Pol 2006;64:397-402.21. Schalekamp T et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther 2006;80:13-22.22. Visser LE et al. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants. Clin Pharmacol Ther 2005;77:479-85.23. Visser LE et al. The risk of bleeding complications in patients with cytochrome' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy. Pharmacogenomics 2008;9:1237-50.13. Gonzalez-Conejero R et al. The genetic interaction of VKORC1 c1173t/calumenin a29809g modulates the anticoagulant response of acenocoumarol. J Thromb Haemost 2007;5:1701-6.14. Schalekamp T et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther 2006;80:13-22.15. Montes R et al. The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients. Br J Haematol 2006;133:183-7.16. Reitsma PH et al. A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med 2005;2:e312.17. Bodin L et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005;106:135-140.Date 10-09-2018CYP2D6' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='Diagn Ther 2010;14:23-30.10. Stepien E et al. A vitamin K epoxide reductase-oxidase complex gene polymorphism (-1639G>A) and interindividual variability in the dose-effect of vitamin K antagonists. J Appl Genet 2009;50:399-403.11. Teichert M et al. Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period. Clin Pharmacol Ther2009;85:379-86.12. Montes R et al. The influence of polymorphisms of VKORC1 and CYP2C9 on major gastrointestinal bleeding risk in anticoagulated patients. Br J Haematol 2008;143:727-33.13. Markatos CN et al. VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients. Pharmacogenomics 2008;9:1631-8.14. Spreafico M et al. Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy. Pharmacogenomics 2008;9:1237-50.15. Gonzalez-Conejero R et al. The genetic interaction of VKORC1' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther 2006;80:13-22.23. Visser LE et al. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants. Clin Pharmacol Ther 2005;77:479-85.24. Visser LE et al. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Thromb Haemost 2004;92:61-6.25. Morin S et al. Pharmacogenetics of acenocoumarol pharmacodynamics. Clin Pharmacol Ther 2004;75:403-14.26. Schalekamp T et al. Acenocoumarol stabilization is delayed in CYP2C9*3 carriers. Clin Pharmacol Ther 2004;75:394-402.27. Visser LE et al. The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics 2004;1427-33.28. Thijssen HH et al. Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype. Clin Pharmacol Ther' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='29. Verstuyft C et al. Genetic and environmental risk factors for oral anticoagulant overdose. Eur J Clin Pharmacol 2003;58:739-45.30. Tassies D et al. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation. Haematologica 2002;87:1185-91.31. Thijssen HH et al. The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol. Pharmacogenetics 2000;10:757-60.Date 14-05-2018CYP2C9*3/*3: acenocoumarol1867NO action is needed for this gene-drug interaction.Genetic variation may lead to a decrease in the required maintenance dose and possibly an increase in the time needed to reach a stable INR. However, there is insufficient evidence that this causes problems when therapyis initiated as usual (i.e. with frequent INR monitoring).Literature:1. Varnai R et al. CYP2C9 and VKORC1 in therapeutic dosing and safety of acenocoumarol treatment: implication for clinical practice in Hungary.' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='R et al. The genetic interaction of VKORC1 c1173t/calumenin a29809g modulates the anticoagulant response of acenocoumarol. J Thromb Haemost 2007;5:1701-6.16. Schalekamp T et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther 2006;80:13-22.17. Montes R et al. The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients. Br J Haematol 2006;133:183-7.18. Reitsma PH et al. A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med 2005;2:e312.19. Bodin L et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005;106:135-140.Date 10-09-2018VKORC1 -1639 GA: acenocoumarol1909NO action is needed for this gene-drug interaction.The genetic variation results in a reduction of the required dose, but' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='2013;369: 2304-12.4. Baranova EV et al. Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes. J Thromb Haemost 2017;15:465-472.5. Verhoef TI et al. Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users. J Thromb Haemost 2012;10:606-14.6. Esmerian MO et al. Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people. J Clin Pharmacol 2011;51:1418-28.7. Kovac MK et al. The c.-1639G>A polymorphism of the VKORC1 gene in Serbian population: retrospective study of the variability in response to oral anticoagulant therapy. Blood Coagul Fibrinolysis 2010;21:558-63.8. Cadamuro J et al. Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements. Eur J Clin Pharmacol 2010;66:253-60.9. Wijnen PA et al. Variant VKORC1 and CYP2C9 alleles in patients with diffuse alveolar hemorrhage caused by oral anticoagulants. Mol Diagn Ther 2010;14:23-30.10. Stepien E et al. A' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='dose requirements in Greek patients. Pharmacogenomics 2008;9:1631-8.18. Spreafico M et al. Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy. Pharmacogenomics 2008;9:1237-50.19. Gonz√°lez-Conejero R et al. The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol. J Thromb Haemost 2007;5:1701-6.20. Beinema MJ et al. The influence of NSAIDs on coumarin sensitivity in patients with CYP2C9 polymorphism after total hip replacement surgery. Mol Diagn Ther 2007;11:123-8.21. Mark L et al. Cytochrome P450 2C9 polymorphism and acenocoumarol therapy. Kardiol Pol 2006;64:397-402.22. Schalekamp T et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther 2006;80:13-22.23. Visser LE et al. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='M et al. Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis. J Thromb Haemost 2014;12:1480-7.5. Stergiopoulos K et al. Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials. JAMA Intern Med 2014;174:1330-8.6. Jin B et al. The impact of VKORC1-1639G\u2009>\u2009A genetic polymorphism upon warfarin dose requirement in different ethnic populations. Curr Med Res Opin 2014;30:1505-11.7. Yang J et al. Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis. Int J Cardiol 2013;168:4234-43.8. Jorgensen AL et al. Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS One 2012;7:e44064.9. Yang L et al. Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement--a systematic' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='12. Cadamuro J et al. Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements. Eur J Clin Pharmacol 2010;66:253-60.13. Wijnen PA et al. Variant VKORC1 and CYP2C9 alleles in patients with diffuse alveolar hemorrhage caused by oral anticoagulants. Mol Diagn Ther 2010;14:23-30.14. Teichert M et al. Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period. Clin Pharmacol Ther2009;85:379-86.15. Montes R et al. The influence of polymorphisms of VKORC1 and CYP2C9 on major gastrointestinal bleeding risk in anticoagulated patients. Br J Haematol 2008;143:727-33.16. Markatos CN et al. VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients. Pharmacogenomics 2008;9:1631-8.17. Spreafico M et al. Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy. Pharmacogenomics' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='Literature:1. Cerezo-Manchado JJ et al. Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment. Pharmacogenomics 2014; 15: 987-96.2. Verhoef TI et al. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. NEJM 2013;369: 2304-12.3. Verhoef TI et al. Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users. J Thromb Haemost 2012;10:606-14.4. Esmerian MO et al. Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people. J Clin Pharmacol 2011;51:1418-28.5. Kovac MK et al. The c.-1639G>A polymorphism of the VKORC1 gene in Serbian population: retrospective study of the variability in response to oral anticoagulant therapy. Blood Coagul Fibrinolysis 2010;21:558-63.6. Cadamuro J et al. Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements. Eur J Clin Pharmacol 2010;66:253-60.7. Wijnen PA et al. Variant VKORC1' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}


Question: What pharmacogenomic factors in the IFNL3 gene are important when prescribing antivirals?

Answer: I'm sorry, but the information provided in the prompt does not include specific details about the pharmacogenomic factors in the IFNL3 gene that are important when prescribing antivirals. It's important to consult with a healthcare professional or a genetic counselor for personalized advice based on a comprehensive evaluation of the individual's genetic profile and overall health status.
Sources:
page_content='\x0626. Clin Infect Dis 2007;45:1230-7. PubMed PMID: 17918089.17. Burger D et al. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol2006;61:148-54.18. Haas DW et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult Aids Clinical Trials Group study. J Infect Dis 2005;192:1931-42. PubMed PMID:16267764.' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='Mart√≠n AS et al. Dose reduction of efavirenz: an observational study describing cost-effectiveness, pharmacokinetics and pharmacogenetics. Pharmacogenomics 2014;15:997-1006.9. Bertrand J et al. Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia. J InfectDis 2014;209:399-408.10. Sarfo FS et al. Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients. J Antimicrob Chemother 2014;69:491-9.PubMed PMID: 24080498.11. Ngaimisi E et al. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.PLoS One 2013;8:e67946. PubMed PMID: 23861838.12. Yimer G et al. High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='fatigue induced by irinotecan-based chemotherapy. Cancer2006;106:1007-16.24. Wright MA et al. A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors.Clin Cancer Res 2005;11:4144-50.25. Kweekel DM et al. Ondersteuning van de chemotherapiekeuze. Pharm Weekblad 2005;20:685-7.26. Steiner M et al. 5-fluorouracil/irinotecan induced lethal toxicity as a result of a combined pharmacogenetic syndrome: report of a case. J Clin Pathol 2005;58:553-5.27. Soepenberg O et al. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors. Clin Cancer Res 2005;11:1504-11.28. Zhou Q et al. Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. Br J Clin Pharmacol 2005;59:415-24.29. Marcuello E et al. UGT1A1 gene variations and irinotecan treatment in' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='\x0628. Pharmacogenet Genomics 2007;17:497-504.15. Stewart CF et al. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. J Clin Oncol 2007;25:2594-600.16. C√¥t√© JF et al. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 2007;13:3269-75.17. Ramchandani RP et al. The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. J Clin Pharmacol 2007;47:78-86.18. Z√°rate Romero R et al. Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients. Oncol Rep' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='with cytochrome P450 2B6 *6 and *26. Clin Infect Dis 2007;45:1230-7. PubMed PMID: 17918089.19. Haas DW et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult Aids Clinical Trials Group study. J Infect Dis 2005;192:1931-42. PubMed PMID:16267764.20. SPC‚Äôs Efavirenz Mylan en Sustiva (VS).21. ENCORE1 Study Group. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial.Lancet 2014;383:1474-82.Date 05-03-2018CYP2D6 IM: eliglustat6138This gene variation reduces the conversion of eliglustat to inactive metabolites. However, in the absence of CYP2D6 and CYP3A inhibitors, this does not result in a clinically significant increased risk of side effects.Recommendation:Co-medication with BOTH a MODERATE to STRONG CYP2D6 INHIBITOR AND a MODERATE to STRONG CYP3A INHIBITOR:Eliglustat is contra-indicated.1.' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='3. Goetz MP et al. UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine. Invest New Drugs 2013;31:1559-67.4. Denlinger CS et al. Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol 2009;65:97-105.5. Minami H et al. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1\x07\x06\x08' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content="for optimal efavirenz exposure in children 3-36 months with HIV infection. AIDS 2017;31:1129-1136.3. Leger P et al. Pharmacogenetics of efavirenz discontinuation for reported central nervous system symptoms appears to differ by race. Pharmacogenet Genomics 2016;26:473-80.4. Cusato J et al. Efavirenz pharmacogenetics in a cohort of Italian patients. Int J Antimicrob Agents 2016;47:117-23.5. Dickinson L et al. Comprehensive pharmacokinetic, pharmacodynamic and pharmacogenetic evaluation of once-daily efavirenz 400 and 600 mg in treatment-na√Øve HIV-infected patients at 96 weeks: results of theENCORE1 study. Clin Pharmacokinet 2016;55:861-73.6. Swart M et al. An expanded analysis of pharmacogenetics determinants of efavirenz response that includes 3'-UTR single nucleotide polymorphisms among black South African HIV/AIDS patients. Front Genet2016;6:356.7. Meng X et al. Effect of CYP2B6 gene polymorphisms on efavirenz plasma concentrations in Chinese patients with HIV infection. PLoS One" metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='J Natl Cancer Inst 2007;99:1290-5.18. Minami H et al. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1\x07\x06\x08' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.PLoS One 2013;8:e67946. PubMed PMID: 23861838.13. Yimer G et al. High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of na√Øve HIV patients from Ethiopia: a prospective cohort study.Pharmacogenomics J 2012;12:499-506. PubMed PMID: 21862974.' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='Thrombolysis 2015; 39:228-34.2. Xu H et al. Meta-analysis of efficacy and safety of genotype-guided pharmacogenetic dosing of warfarin. Int J Cardiol 2014; 177:654-7.3. Franchini M et al. Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis. J Thromb Haemost 2014; 12:1480-7.4. Stergiopoulos K et al. Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials. JAMA Intern Med 2014; 174:1330-8.5. Yang J et al. Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis. Int J Cardiol 2013; 168:4234-43.6. Jorgensen AL et al. Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS One 2012; 7:e44064.7. Lindh JD et al. Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='IM: irinotecan1691NO action is needed for this gene-drug interaction.This genetic variation (IM) is more common in Western populations than the wild-type (&\x01\x03*1). This means that treatment is largely geared to patients with this genetic variation. Adjustment of the treatment is thereforenot useful.Literature:1. Chen X et al. UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with lung cancer: a meta-analysis. Cancer Chemother Pharmacol 2017;79:1109-1117.2. Chen YJ et al. The association of UGT1A1\x07\x06\x08' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='with efavirenz-based HAART-induced liver injury in the treatment of na√Øve HIV patients from Ethiopia: a prospective cohort study.Pharmacogenomics J 2012;12:499-506. PubMed PMID: 21862974.13. Mugusi S et al. Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania. PLoS One 2012;7:e40180. PubMed PMID:22808112.14. Wyen C et al. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. J Antimicrob Chemother2011;66:2092-8. PubMed PMID: 21715435.15. Carr DF et al. Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort. J Antimicrob Chemother 2010;65:1889-93. PubMed PMID: 20639527.16. Gatanaga H et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 \x07\x06\x08' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}


